Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

Rhea-AI Summary

Syndax Pharmaceuticals, Inc. (SNDX) announced its participation in the Goldman Sachs 42nd Annual Global Healthcare Conference scheduled for June 10, 2021, at 2:10 p.m. ET. Management will present details about the company’s innovative cancer therapy pipeline, including SNDX-5613, axatilimab, and entinostat. The live presentation will be accessible through the Investor section of Syndax's website, with a replay available for a limited time afterward.

Positive

• Participation in a prestigious healthcare conference may enhance visibility and attract investor interest.

Negative

• None.

WALTHAM, Mass., June 3, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 2:10 p.m. ET.

A live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842

SNDX-G

 

View original content:http://www.prnewswire.com/news-releases/syndax-announces-participation-in-goldman-sachs-42nd-annual-global-healthcare-conference-301304926.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When will Syndax Pharmaceuticals present at the Goldman Sachs Conference?

Syndax Pharmaceuticals will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 2:10 p.m. ET.

What is the significance of Syndax's participation in the Goldman Sachs Conference?

Participation in the Goldman Sachs Conference could enhance Syndax's visibility in the healthcare sector and attract potential investors.

How can I access the webcast of Syndax's presentation?

The webcast of Syndax's presentation can be accessed from the Investor section of their website at www.syndax.com.

What therapies are included in Syndax's pipeline?

Syndax's pipeline includes SNDX-5613, axatilimab, and entinostat, focusing on innovative cancer treatments.